Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07231991 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
A Phase 1 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07231991 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT07231991, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relative to people with normal liver function. This study is seeking participants who are: * females who cannot have children or males * between 18 and 70 years of age * weigh more than 50 Kilograms (110 pounds) * either healthy with normal liver function or have loss of liver function All participants in this study will take one dose of vepdegestrant by mouth. This study looks at how the medicine is changed and removed from the body after being taken by the participants. The amount of vepdegestrant in participants with loss of liver function will be compared to the amount of vepdegestrant in participants with normal liver function. All participants will stay at the study clinic for about 11 days and 10 nights.
Interventions
- DRUG vepdegestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2026-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07231991
The ClinicalTrials.gov registry entry for NCT07231991 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vepdegestrant is the first listed.
NCT07231991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07231991 about?
NCT07231991 is a clinical study titled "A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function". The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relative to people with normal liver function. This study is seeking participants who are: * females who cannot have children or males * between 18 and 70...
What is the current status of trial NCT07231991?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-11-18. Estimated completion is 2026-12-23.
What interventions are being tested in trial NCT07231991?
The interventions under investigation include: vepdegestrant (DRUG).
Who is sponsoring clinical trial NCT07231991?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.